about
Vascular endothelial growth factor increases heme oxygenase-1 protein expression in the chick embryo chorioallantoic membraneNAD(P)H oxidase modulates angiogenesis and the development of portosystemic collaterals and splanchnic hyperaemia in portal hypertensive rats.Hepatic endothelial dysfunction and abnormal angiogenesis: new targets in the treatment of portal hypertension.Sequential Functions of CPEB1 and CPEB4 Regulate Pathologic Expression of Vascular Endothelial Growth Factor and Angiogenesis in Chronic Liver Disease.Molecular pathophysiology of portal hypertension.New approaches in the pharmacologic treatment of portal hypertension.Disruption of negative feedback loop between vasohibin-1 and vascular endothelial growth factor decreases portal pressure, angiogenesis, and fibrosis in cirrhotic rats.Evidence against a role for inducible nitric oxide synthase in the hyperdynamic circulation of portal-hypertensive rats.Relevance of the mTOR signaling pathway in the pathophysiology of splenomegaly in rats with chronic portal hypertension.Increased heme oxygenase activity in splanchnic organs from portal hypertensive rats: role in modulating mesenteric vascular reactivity.Effects of the V1a vasopressin agonist F-180 on portal hypertension-related bleeding in portal hypertensive rats.Simvastatin enhances hepatic nitric oxide production and decreases the hepatic vascular tone in patients with cirrhosis.Anti-VEGF receptor-2 monoclonal antibody prevents portal-systemic collateral vessel formation in portal hypertensive mice.Neonatal capsaicin treatment does not prevent splanchnic vasodilatation in portal-hypertensive rats.Pathophysiology of portal hypertension.Antiangiogenic and antifibrogenic activity of pigment epithelium-derived factor (PEDF) in bile duct-ligated portal hypertensive ratsThe eNOS cofactor tetrahydrobiopterin improves endothelial dysfunction in livers of rats with CCl4 cirrhosisAlterations in soluble and leukocyte surface L-selectin (CD 62L) in hemodialysis patientsAcute and chronic cyclooxygenase blockage in portal-hypertensive rats: influence in nitric oxide biosynthesisMechanical pumping of portal blood to the liver: hemodynamic effects of a new experimental treatment for portal hypertensionNoninvasive measurement of femoral blood flow and portal pressure response to propranolol in patients with cirrhosisImpaired function of pancreatic islets from rats with portal hypertension resulting from cirrhosis and partial portal vein ligationGastric microcirculatory changes of portal-hypertensive rats can be attenuated by long-term estrogen-progestagen treatmentEffects of ritanserin, a selective and specific S2-serotonergic antagonist, on portal pressure and splanchnic hemodynamics in rats with long-term bile duct ligationDuration of the hemodynamic effects of N(G)-nitro-L-arginine methyl ester in vivoIncreased heme oxygenase-1 gene expression in liver cells and splanchnic organs from portal hypertensive ratsReversal of portal hypertension and hyperdynamic splanchnic circulation by combined vascular endothelial growth factor and platelet-derived growth factor blockade in ratsHeme oxygenase attenuates oxidative stress and inflammation, and increases VEGF expression in portal hypertensive ratsEffects of the combined administration of propranolol plus sorafenib on portal hypertension in cirrhotic ratsRole and therapeutic potential of vascular stem/progenitor cells in pathological neovascularisation during chronic portal hypertension
P50
Q35045371-F8F17AF2-5F84-46F8-81C4-C04DC1CD0952Q35761411-6CB2BDA2-CC3C-4172-BE29-339DD93B8087Q37766339-CD7E146E-555E-4ACB-A97C-0BF5C37C24E1Q38815138-5E093B21-EA7D-4F27-A0D7-7C18EAB0E108Q39148718-98E6B4A8-CDEA-4FA6-8417-0CCA58560797Q40709930-BBCA88A5-BAB4-42A7-9DD4-9161C8D24A1AQ42245190-0A1DB3B0-48C3-4870-9A9B-18E04BB3D359Q42275656-4F1B10F4-60F9-4278-8899-5864759322D6Q43141347-77F3379C-3771-49C8-8E61-3BBF1E90AC1FQ43672258-D59D8D86-205F-4402-ACBD-70F7B5A205A4Q44675023-6A8C4A26-EB69-4839-8DAA-DDB8942EB289Q44779682-F9CE852D-AB05-4537-AD05-1012E45394D3Q48026378-A7BC62DB-5A9F-41C8-B9F7-98926F5326ECQ51617775-A6110AB7-04F2-47AD-9515-3C298316B3C6Q54274405-374302EC-A454-4BC4-8FCA-1FA942B47CD1Q57145837-71B4A7D8-85C3-4198-A275-731CF12D1F90Q62078862-F80D2116-CA0A-4DEE-9D4D-39AC2500F137Q70971722-9E1204E3-1F23-40FD-BC9C-97CE287ED260Q71035939-8822C613-D805-4582-BD67-826DD4F5CE12Q71605623-A02CD618-E53C-49BA-A491-0B4EB0562BAEQ72371473-785AA0D6-6949-4AE6-9386-89A75CA8D214Q72402216-418ACE97-FCE4-4902-A7EB-C4F8900995B1Q72719885-2769EFFA-22D4-4F40-A3F1-2EA265C54C15Q72853759-F457E427-B320-493E-AE8C-74E7BBBA5F4AQ73843231-DFB727A4-8987-4826-B83A-CA097DAFC531Q77807952-BCD1A8B2-736B-4AFA-9E5F-164B5B6054DFQ80678101-1EB66B4C-D8F6-4B8F-9232-73EA897778AFQ82471490-1BB99753-AB55-4581-80A5-CD916658C5D1Q83612487-00A1018D-CE13-4261-BD1F-07AD18560216Q87475232-EE7AFA3E-EE16-4E84-93B2-543108514EF1
P50
description
Forscher
@de
Spanish biomedical researcher
@en
chercheur
@fr
investigador
@es
ricercatore
@it
wetenschapper
@nl
研究者
@zh
name
Fernández M
@ast
Fernández M
@es
Fernández M
@nl
Mercedes Fernández
@en
type
label
Fernández M
@ast
Fernández M
@es
Fernández M
@nl
Mercedes Fernández
@en
altLabel
Fernández M
@en
Mercedes Fernandez Lobato
@en
prefLabel
Fernández M
@ast
Fernández M
@es
Fernández M
@nl
Mercedes Fernández
@en
P106
P31
P496
0000-0002-5270-4304